Checkpoint blockade and microsatellite instability

Patent metadata

Field	Value
Publication number	US-11634491-B2
Application number	US-202217739278-A
Country	US
Kind code	B2
Filing date	May 9, 2022
Priority date	Nov 13, 2014
Publication date	Apr 25, 2023
Grant date	Apr 25, 2023

Abstract

Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.

First claim

We claim:

1. A method of treating cancer in a human patient, the method comprising:
testing or having tested a biological sample obtained from a patient having endometrial cancer, small bowel cancer, gastric cancer, ampullary cancer, choloangiocarcinoma, pancreatic cancer, prostate cancer, breast cancer, esophageal cancer, liver cancer, ovarian cancer, uterine cancer, cervical cancer, bladder cancer, testicular cancer or oral cancer, thereby determining that the patient's cancer is microsatellite instability high or DNA mismatch repair deficient; and
in response to determining that the patient's cancer is microsatellite instability high or DNA mismatch repair deficient, treating the patient determined to have microsatellite instability high or DNA mismatch repair deficient cancer with a therapeutically effective amount of pembrolizumab.

2. The method of claim 1 , wherein the biological sample is tumor tissue.

3. The method of claim 1 , wherein the biological sample is a body fluid.

4. The method of claim 1 , wherein the cancer is endometrial cancer, small bowel cancer, gastric cancer, ampullary cancer or choloangiocarcinoma.

5. The method of claim 1 , wherein the cancer is pancreatic cancer, prostate cancer, breast cancer, esophageal cancer, liver cancer, ovarian cancer, uterine cancer, cervical cancer, bladder cancer, testicular cancer or oral cancer.

6. The method of claim 1 , wherein the cancer is determined to be microsatellite instability high.

7. The method of claim 1 , wherein the cancer is determined to be mismatch repair deficient.

8. The method of claim 1 , wherein the testing or having tested comprises carrying out or having carried out an immunohistochemistry test on the sample.

9. The method of claim 1 , wherein the testing or having tested comprises carrying out or having carried out a polymerase chain reaction on the sample.

10. The method of claim 1 , wherein the testing or having tested comprises carrying out or having carried out next generation sequencing on the sample.

11. The method of claim 1 , wherein the pembrolizumab is administered to the patient intravenously.

12. The method of claim 1 , wherein the cancer is small bowel cancer.

13. The method of claim 1 , wherein the patient had previously been treated with a prior cancer therapy drug and the patient's cancer had progressed after the patient was treated with the prior cancer therapy drug.

14. The method of claim 1 further comprising testing or having tested the patient for progression of the cancer after the treatment.

15. The method of claim 1 , wherein the cancer is metastatic.

16. A method of reducing the risk of cancer progression or increasing overall survival in a human patient, the method comprising:
testing, or having tested, a biological sample obtained from a patient having endometrial cancer, small bowel cancer, gastric cancer, ampullary cancer, choloangiocarcinoma, pancreatic cancer, prostate cancer, breast cancer, esophageal cancer, liver cancer, ovarian cancer, uterine cancer, cervical cancer, bladder cancer, testicular cancer or oral cancer, thereby determining that the patient's cancer is microsatellite instability high or DNA mismatch repair deficient; and
in response to determining that the patient's cancer is microsatellite instability high or DNA mismatch repair deficient, treating the patient determined to have microsatellite instability high or mismatch repair deficient cancer with a therapeutically effective amount of pembrolizumab.

17. The method of claim 16 , wherein the biological sample is a tumor tissue sample from the patient.

18. The method of claim 16 , wherein the biological sample is a body fluid from the patient.

19. The method of claim 16 , wherein the cancer is endometrial cancer, small bowel cancer, gastric cancer, ampullary cancer or choloangiocarcinoma.

20. The method of claim 16 , wherein the cancer is pancreatic cancer, prostate cancer, breast cancer, esophageal cancer, liver cancer, ovarian cancer, uterine cancer, cervical cancer, bladder cancer, testicular cancer or oral cancer.

21. The method of claim 16 , wherein the cancer is determined to be microsatellite instability high.

22. The method of claim 16 , wherein the cancer is determined to be mismatch repair deficient.

23. The method of claim 16 , wherein the testing or having tested comprises carrying out or having carried out an immunohistochemistry test on the sample.

24. The method of claim 16 , wherein the testing or having tested comprises carrying out or having carried out a polymerase chain reaction on the sample.

25. The method of claim 16 , wherein the testing or having tested comprises carrying out or having carried out next generation sequencing on the sample.

26. The method of claim 16 , wherein the pembrolizumab is administered to the patient intravenously.

27. The method of claim 16 , wherein the cancer is small bowel cancer.

28. The method of claim 16 , wherein the patient had previously been treated with a prior cancer therapy drug and the patient's cancer had progressed after the patient was treated with the prior cancer therapy drug.

29. The method of claim 17 further comprising testing or having tested the patient for progression of the cancer after the treatment.

30. The method of claim 16 , wherein the cancer is metastatic cancer.

31. The method of claim 1 , wherein the cancer is endometrial cancer.

32. The method of claim 31 , wherein the patient had previously been treated with a prior cancer therapy drug and the patient's cancer had progressed after the patient was treated with the prior cancer therapy drug.

33. The method of claim 31 further comprising testing or having tested the patient for progression of the cancer after the treatment.

34. The method of claim 31 , wherein the cancer is metastatic.

35. The method of claim 16 , wherein the cancer is endometrial cancer.

36. The method of claim 35 , wherein the patient had previously been treated with a prior cancer therapy drug and the patient's cancer had progressed after the patient was treated with the prior cancer therapy drug.

37. The method of claim 35 further comprising testing or having tested the patient for progression of the cancer after the treatment.

38. The method of claim 35 , wherein the cancer is metastatic.

Assignees

• Univ Johns Hopkins

Inventors

• Diaz Luis
• Vogelstein Bert
• Kinzler Kenneth W
• Papadopoulos Nickolas
• Le Dung
• Pardoll Drew M
• Topalian Suzanne L

Classifications

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C12Q2600/156

  Polymorphic or mutational markers · CPC title

• C12Q1/6886

  for cancer (immunoassay for cancer G01N33/575) · CPC title